MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the latter’s new investigational programmed cell death 1 (PD-1)/vascular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback